Table 2.
Oncological features of patient cohort.
| Histology (N; %) | Lung adenocarcinoma (33; 70.2) Lung squamous cells carcinoma (14; 29.8) |
| Tumor stadium (N; %) | I (0; 0) II (0; 0) IIIA/IIIB (6; 12.8) IV (41; 87.2) |
| ICI Therapy (N; %) | 47; 100 PD-1 Inhibitors (26; 55.3) Nivolumab (7; 14.9) Pembrolizumab (19; 40.2) PD-L1 Inhibitors (12; 25.5) Atezolizumab (8; 17) Durvalumab (4; 8.5) Combination of ICI + CHT (9; 19.1) |
| Previous ICI Therapy, N (%) | 1 (2.1) |
| CHT before ICI therapy, N (%) | 28 (59.6) |
| RT during ICI therapy, N (%) | 1 (2.1) |
| RT before ICI therapy, N (%) | 22 (46.8) |
| Previous surgery, N (%) | 16 (34) |
| PD-1 Expression > 50%, N (%) | 25 (53.2) |
| PD-1 Expression ≤ 50%, N (%) | 22 (46.8) |
Abbreviations: CHT, chemotherapy; ICI, immune checkpoint inhibitor; PD-1, programmed cell death 1; PD-L1, programmed cell death 1-ligand; RT, radiotherapy.